Cardium Therapeutics, Inc. (CXM) Promotes Wellness and Prevention

When Cardium Therapeutics recently acquired To Go Brands, a San Diego based nutraceuticals developer, it was a major expansion of Cardium’s original Medpodium nutraceutical line, and reflective of the company’s support for the nutraceutical side of their business. Cardium, known for its developments in the area of regenerative medicine, is also becoming a growing player in the area of wellness and disease prevention. To Go Brand products cover a range of weight-loss and energy markets for active professionals, but also include the following offerings designed to promote basic nutritional health:

• Healthy Belly is a probiotic digestive mix of live “friendly” bacteria that are beneficial when consumed daily for maintaining digestive balance. For hundreds of years dairy foods containing live cultures have been touted as having beneficial digestive and intestinal properties. Now increasing numbers of health-conscious people are seeking more convenient ways to add the benefits of probiotics to their diets. Each packet contains natural probiotic cultures plus fiber that can help regulate the digestive system.

• Go Greens Super Fruits & Veggies is packed with more than 15 organic fruits and veggies to provide an antioxidant powder equivalent to 6 servings of fruits and vegetables, and with a great taste. One serving of Go Greens has an Oxygen Radical Absorbance Capacity (ORAC) value of 4000. As a comparison, a serving of broccoli has an ORAC value of 700.

• Omega To Go provides 100 mg of Vegetarian Omega in an orange dreamsicle flavor, is packed with antioxidants from Vitamins A, C, E, and D, and is a good source of fiber for healthy digestion. It also contains life’sDH™, one of the only vegetarian sources of DHA on the market today. Unlike oils derived from fish that may be high in ocean-borne contaminants, life’sDH™ comes from eco-friendly, sustainable algae. Fish actually get their high DHA content by eating algae, and life’sDH™ simply eliminates the “middle fish.”

For additional information, visit www.CardiumTHX.com and www.ToGoBrands.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Charles & Colvard Ltd. (CTHR) Captures Growing Global Jewelry Market via Cutting-Edge Gem Technology and Innovations in Brand Presence

Charles & Colvard is the sole global producer of moissanite, an exceptionally pure gemstone comprised of the world’s second hardest substance, silicon carbide. Moissanite was originally discovered in Arizona’s Meteor Crater and is highly-prized for its scintillating brilliance (or the amount of light reflected from the “crown” to the eye, here being massive due to a refractive index in the 2.65 to 2.69 range), adamantine luster (diamond-like quantity/quality of reflected light from the surface), and fire (the tendency of the gem to split light into its spectrum of colors), all of which surpass that of the finest diamond.

The company actively produces Charles & Colvard Created Moissanite® The Most Brilliant Jewel in the World® for rapidly expanding end markets across the jewelry landscape via a patent-protected process (which was even recently upheld by the USPTO after an ex parte re-examination) of growing raw silicon carbide crystals into the kinds and shapes of gem-quality stones most desired for jewelry. Growing functional gem-stone sized moissanite, which naturally occurs only in very small crystals, is a feat that took decades of research to perfect. Every gemstone that leaves the facility passes through the hands of the company’s master cutters who polish and facet the stones to precisely calculated specifications (taking science into the realm of art), ensuring that every single jewel passes muster with CTHR’s exacting standards for clarity, color, and cut (with a 5mm laser inscription on the girdle of each gem to verify these quality control measures).

The cream of the crop from this process end up in the company’s signature, Forever Brilliant® brand of premium moissanite stones (with a hardness of 9.25 these stones will remain gorgeous for generations and each one comes with both a certificate of authenticity and a limited lifetime warranty), which sparkle with a noticeably brighter, near colorless shade of white that is up to four grades whiter than the standard moissanite. The level of visual appeal is immediately apparent as this high-quality moissanite is 10% more brilliant than diamond, and after CTHR master cutters have done their work, the end result is a gemstone more beautiful than the best diamonds at a tenth of the cost. The icy color of this stone complements platinum settings superbly and can catch the light of a candle flame from across the room, as the facets explode with a multihued rainbow of brilliance – something made possible by CTHR’s proprietary two-stage enhancement process that ends with a purification of the crystal lattice work itself.

The strategic advantage of being the sole global source for moissanite puts CTHR in the enviable position of being able to pursue an efficient brand identity vector, emphasizing superior gem quality/affordability on the one hand (especially compared to the diamond industry) and its trend-setting designs, as well as retail venues/brands on the other. The company recently overhauled the website for the first of their two retail jewelry divisions, Moissanite.com, an e-commerce portal designed to enhance market traction while educating consumers about the beauty/value of the Charles & Colvard Created Moissanite gems (as well as the stunning jewelry into which they are incorporated).

The second, highly visible retail venue for CTHR is Lulu Avenue™, which focuses on branded direct sales/e-commerce of elegant jewelry designs, leaning heavily on the company’s continued work with top jewelry designers throughout the industry to bring the hottest, in-trend offerings to consumers. Lulu Avenue is also the only direct sales-based jewelry trunk show operator around, bringing special sales of merchandise directly to select venues and retail locations, adding a key channel for CTHR that really shows in the bottom line. This also engages target market cohesion as customers are invited to host their own jewelry trunk shows and earn free top-of-the-line jewelry, with the company even going so far as to offer a chance to join forces and become a Lulu Avenue Independent Style Advisor. The company has done a great job putting Charles & Colvard Created Moissanite on the map with this kind of market engagement innovation and it really comes through in the latest financial data.

The recent report (Oct 25) of a 75% jump in Q3 2012 (ended Sept 30) net sales when compared with the same period in 2011 (up to $5.1M from $2.9M) , spurred on by strong results from investment in the consumer-direct business segments, showed clear top-line revenue growth. The first three quarters of the year were up 60% over the same period in 2011. The company also reported $11.9M in cash and investments with no long-term debt, strong indicators on the back of positive cash flow from operations totaling $689k in Q3 ($2.1M year-to-date). Finished jewelry sales alone jumped 147% to $4M (from $1.6M), showing solid end-market contacts are established for the growing gem after market.

CEO of CTHR, Randy N. McCullough, emphasized leveraging the investments made in the Lulu Avenue and Moissanite.com channels to create future recurring revenue, profitability, and shareholder growth metrics, as well as the exciting financial results from expansion of the company’s “powerful collection of brands.” The exclusive services/licensing agreement announced earlier (Oct 22) in the same week with JudeFrances Jewelry, to design custom fashion and moissanite pieces for Lulu Avenue, further shows CTHR’s prowess when it comes to charming today’s most coveted designers who can add vital trend-setting work and cache value to the overall commercial pipeline.

Strong response from the industry at the JCK jewelry trade show (biggest industry trade show in the U.S.) in Las Vegas to the Forever Brilliant launch in Q2 2012 boosted wholesale gemstone sales considerably, accounting for 25% of loose stone sales volume (Created Moissanite representing the remainder). Loose gemstone sales were up on the whole some 43% to roughly $10.3M (from $7.2M).

A product born of ancient stardust today finds its way into the hands of millions through CTHR’s ingenious technology and marketing. Whether it is as loose stones destined for other designs or incorporated into the company’s own aesthetic marvels, moissanite is gaining serious ground in its category as an affordable diamond alternative with superior evocation of the qualities most sought after in such gemstones.

For more information on Charles & Colvard, visit www.CharlesAndColvard.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

LiqTech International, Inc. (LIQT) and Denovo Enter OEM Supply Deal

LiqTech International, a clean technology company, recently signed an OEM supply agreement with Shanghai Denovo Environment Protection Co. Ltd. China, which will utilize LiqTech’s SiC membrane technology as a key component for its near-term projects.

“Through our comprehensive experience and partnership with LiqTech, I believe the collaboration will expand the boundaries in the water treatment industry,” Dr Chen Yegang, chairman of Denovo stated in the press release. “We have near-term projects at hand where we will utilize the SiC membrane as a key process component. The LiqTech membrane technology is superior in its field, and will add value for our customers.”

As a leading industrial waste water firm in China, Denovo is targeting one of the fastest growing markets for industrial wastewater treatment. Chinese environmental legislation has called for increasing stringent discharge limits for water treatment, which Denovo said it believes it can provide by using its biological treatment systems paired with LiqTech’s SiC membrane technology.

“Denovo is a leading Chinese EPC contractor of wastewater treatment plants, and the company has shown remarkable growth in a strategic market to LiqTech. This agreement with Denovo is a milestone for LiqTech in our efforts to penetrate the Chinese market for water treatment with our SiC membranes,” LiqTech CEO Lasse Andreassen stated in the press release.

Per the OEM agreement, Denovo will place progressive minimum order quantities for the years 2013-2016 in order to maintain the supply agreement.

For more information visit www.liqtech.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Atossa Genetics, Inc. (ATOS) Adds Christopher S. Destro as VP – Sales and Marketing

Atossa Genetics recently announced that Christopher S. Destro has joined the company as its new Vice President of Sales and Marketing. An industry veteran with over 16 years of successful sales and client management expertise, Mr. Destro will oversee product marketing, distribution, and sales. He will report to Dr. Steven C. Quay, MD, PhD, FCAP, Chairman, CEO and President.

“[Atossa] is very fortunate to have Christopher Destro join us as Vice President of Sales and Marketing at this pivotal time,” remarked Dr. Quay. “As we accelerate the national roll-out of our ForeCYTE and ArgusCYTE Breast Health Tests in early 2013, Chris’ extensive industry experience and in-depth market and technical expertise will be invaluable in helping us achieve our ambitious growth objectives.”

From 2007 to 2011, Mr. Destro held multiple prominent positions, including Vice President of Sales, North America, for three divisions of Magellan Biosciences where he managed sales of automated blood culture and automated susceptibility instrumentation for Trek Diagnostics, automated immunochemistry for Dynex, and a lead care platform for Point of Care testing. In July 2011, Thermo Fisher Scientific acquired Magellan, and Mr. Destro became a commercial leader of the Microbiology Division, working with national contracts, distribution channels, and direct sales in the clinical, pharmaceutical, and industrial markets. From 2000 to 2007, Mr. Destro served as Americas Sales Director for International Bioproducts, managing sales of core food pathogen diagnostic (ELISA) products while leading 17 distributors for the United States, Canada, Mexico and Latin America. Mr. Destro holds a Bachelor of Science degree in Microbiology from Ohio State University.

Mr. Destro said, “Atossa Genetics is an exciting and dynamic opportunity and I look forward to working with the team to commercialize the Company’s products and services for the benefit of millions of women. Atossa has already demonstrated the ability to make a difference in women’s lives. Over the past two decades, I have assembled and led teams that have achieved high growth in the diagnostic biotechnology solutions markets. I look forward to contributing to the next phase of Atossa’s growth as we expand the commercialization of our innovative products and services in the U.S.”

He continued, “One of the things that attracted me to Atossa is its novel and revolutionary approach to diagnosing, treating and preventing Breast Cancer. I believe this uniquely positions us to expand the commercialization of our potentially life-saving and market-changing solutions at a time when the need is greater than ever.”

On December 20, 2012, as incentive to join the company, Mr. Destro was awarded an option to purchase a total of 200,000 shares of Atossa’s common stock, par value $0.001 per share, outside the company’s 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.11 per share, the fair market value on the grant date, and vests over a four-year period from his commencement of service.

For more information on Atossa Genetics, visit www.atossagenetics.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html Atossa Genetics, Inc. (ATOS) Adds Christopher S. Destro as VP – Sales and Marketing

Atossa Genetics recently announced that Christopher S. Destro has joined the company as its new Vice President of Sales and Marketing. An industry veteran with over 16 years of successful sales and client management expertise, Mr. Destro will oversee product marketing, distribution, and sales. He will report to Dr. Steven C. Quay, MD, PhD, FCAP, Chairman, CEO and President.

“[Atossa] is very fortunate to have Christopher Destro join us as Vice President of Sales and Marketing at this pivotal time,” remarked Dr. Quay. “As we accelerate the national roll-out of our ForeCYTE and ArgusCYTE Breast Health Tests in early 2013, Chris’ extensive industry experience and in-depth market and technical expertise will be invaluable in helping us achieve our ambitious growth objectives.”

From 2007 to 2011, Mr. Destro held multiple prominent positions, including Vice President of Sales, North America, for three divisions of Magellan Biosciences where he managed sales of automated blood culture and automated susceptibility instrumentation for Trek Diagnostics, automated immunochemistry for Dynex, and a lead care platform for Point of Care testing. In July 2011, Thermo Fisher Scientific acquired Magellan, and Mr. Destro became a commercial leader of the Microbiology Division, working with national contracts, distribution channels, and direct sales in the clinical, pharmaceutical, and industrial markets. From 2000 to 2007, Mr. Destro served as Americas Sales Director for International Bioproducts, managing sales of core food pathogen diagnostic (ELISA) products while leading 17 distributors for the United States, Canada, Mexico and Latin America. Mr. Destro holds a Bachelor of Science degree in Microbiology from Ohio State University.

Mr. Destro said, “Atossa Genetics is an exciting and dynamic opportunity and I look forward to working with the team to commercialize the Company’s products and services for the benefit of millions of women. Atossa has already demonstrated the ability to make a difference in women’s lives. Over the past two decades, I have assembled and led teams that have achieved high growth in the diagnostic biotechnology solutions markets. I look forward to contributing to the next phase of Atossa’s growth as we expand the commercialization of our innovative products and services in the U.S.”

He continued, “One of the things that attracted me to Atossa is its novel and revolutionary approach to diagnosing, treating and preventing Breast Cancer. I believe this uniquely positions us to expand the commercialization of our potentially life-saving and market-changing solutions at a time when the need is greater than ever.”

On December 20, 2012, as incentive to join the company, Mr. Destro was awarded an option to purchase a total of 200,000 shares of Atossa’s common stock, par value $0.001 per share, outside the company’s 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.11 per share, the fair market value on the grant date, and vests over a four-year period from his commencement of service.

For more information on Atossa Genetics, visit www.atossagenetics.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Novatel Wireless, Inc. (NVTL) Wins Multiple Awards and Ships Three Millionth 4G LTE Device

Novatel Wireless announced recently that since its first shipment in January 2011, Novatel has shipped over three million 4G LTE enabled mobile computing products. On top of reaching this impressive milestone, Novatel Wireless recently won two new LTE innovation awards and multiple Editors’ Choice accolades from tier-one publications for its new 4G LTE MiFi 2.

“We are pleased to celebrate our three millionth shipment of LTE enabled data-only mobile computing products and excited to be honored as the vendor providing continued innovation and the most advanced mobile broadband solutions in the market,” said Peter Leparulo, CEO of Novatel Wireless.

Novatel Wireless’ MiFi 4620L was recently named the winner in the Best LTE Device/Handset category of the 2012 Telecoms LTE North America Awards. The company’s innovative new product was also a CES Innovations Honoree in the Computer Accessories category of the Consumer Electronics Association (CEA)® 2013 Design and Engineering Award. AT&T recently released the MiFi 2 as the MiFi Liberate, and it has already been the recipient of an impressive number of industry awards and Editors’ Choice selections as the best performing and most advanced mobile hotspot on the market.

A recent review by GIZMODO, headlined “AT&T MiFi Liberate: The Best Mobile Hotspot I’ve Ever Used,” stated, “An AT&T LTE MiFi will change your life a little bit.” Highlighting the MiFi Liberate’s bright 2.8-inch color touch-screen display, it continued, “You normally use a computer to change a mobile hotspot’s settings. But this does it on the tiny screen, and it sets the Liberate apart from so much of the competition.” GIZMODO’s review added, “The best part [is] the battery life! This thing will go for days…”

A recent review in PC Magazine noted the advanced feature functionality, ease of use, and reliability of the MiFi Liberate. The review went on to say that the MiFi Liberate “gets you fast 4G LTE data speeds for more than 10 hours on a single charge, plus loads of additional features.” It continued, “The MiFi Liberate for AT&T takes mobile hotspots to the next level. It’s the best hotspot on AT&T, and our Editors’ Choice.”

“We believe our innovative approach, leading design and superior performance are vital factors when serving the mobile broadband market and we’re thrilled to see the acknowledgement and amazing feedback from editors and the industry,” Mr. Leparulo continued.

For further information, please visit www.nvtl.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Global Semiconductor Alliance Awards Entropic Communications, Inc. (ENTR)

Earlier this month, Entropic Communications, a world leader in semiconductor solutions, announced that they were awarded the 2012 GSA Award in the “Most Respected Public Semiconductor Company Achieving $100 million to $250 million in Annual Sales” category by the Global Semiconductor Alliance (GSA).

The GSA’s mission is to accelerate growth and increase the return on investment of the global semiconductor industry by fostering collaboration, integration, and innovation among its industry. The GSA Awards are presented annually to outstanding semiconductor companies worldwide that have demonstrated excellence through their success, vision, and strategy. Award winners are selected by GSA members and are evaluated based on the products and future opportunities associated with a company’s silicon solutions and business model.

“We congratulate Entropic on receiving a prestigious 2012 GSA Award,” said Jodi Shelton, co-founder and president, GSA. “Entropic has undergone an impressive evolution over the past year, making two key acquisitions to further fuel Pay-TV operators’ shift from traditional broadcast to streaming, IP-based video delivery.”

Entropic is the only pure-play platform semiconductor company in connected home entertainment. The company offers a diverse portfolio of connectivity and set-top box (STB) system-on-a-chip (SoC) solutions that reliably and securely deliver and process multimedia digital content into and throughout the home.

“We are honored to be recognized by the GSA and our peers in the semiconductor community for our bold vision and successful execution in expanding our market opportunity in the competitive connected home entertainment market,” said Patrick Henry, president and CEO, Entropic. “With our expanded portfolio, we now offer best-in-class Connectivity and STB System-on-a-Chip solutions that seamlessly power and enable global Pay-TV operators to create more captivating whole-home entertainment experiences for their subscribers.”

In April 2012, Entropic completed its acquisition of Trident Microsystems’ STB SoC business which helped expand its presence in the connected home entertainment market by obtaining complementary assets, intellectual property (IP), patents, and core competencies. It also expanded the company’s international presence and diversified its revenue base. In July 2012, Entropic acquired specific direct broadcast satellite (DBS) IP and corresponding technologies from PLX Technology, Inc. This accelerated its DBS outdoor unit product roadmap.

The Global Semiconductor Alliance (GSA) addresses the challenges within the semiconductor supply chain including IP, EDA/design, wafer manufacturing, testing, and packaging to enable industry-wide solutions. The GSA identifies and articulates market opportunities, encourages and supports entrepreneurship, and provides members with comprehensive and unique market intelligence. Members include companies throughout the supply chain representing 30 countries across the globe. More information can be found at www.gsaglobal.org.

Entropic Communications is a leading global provider of silicon and software solutions that enable connected home entertainment. Entropic transforms how traditional HDTV broadcast and streaming video content is available, ensuring seamless, reliable, and securely delivered, processed, and distributed content into and throughout the home. Entropic’s next-generation home connectivity and set-top box system-on-a-chip (SoC) solutions enable Pay-TV service providers to offer consumers a more captivating whole-home entertainment experience by delivering new, high-performing ways to connect, engage, and enjoy multimedia content. For more information, visit www.entropic.com.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at  www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

LiqTech International, Inc. (LIQT) Inks OEM Supply Deal with Denovo

LiqTech International, a clean technology company, has entered into an OEM supply agreement with Shanghai Denovo Environment Protection Co. Ltd. China, which will utilize LiqTech’s SiC membrane technology as a key component for its near-term projects.

“Through our comprehensive experience and partnership with LiqTech, I believe the collaboration will expand the boundaries in the water treatment industry,” Dr Chen Yegang, chairman of Denovo stated in the press release. “We have near-term projects at hand where we will utilize the SiC membrane as a key process component. The LiqTech membrane technology is superior in its field, and will add value for our customers.”

As a leading industrial waste water firm in China, Denovo is targeting one of the fastest growing markets for industrial wastewater treatment. Chinese environmental legislation has called for increasing stringent discharge limits for water treatment, which Denovo said it believes it can provide by using its biological treatment systems paired with LiqTech’s SiC membrane technology.

“Denovo is a leading Chinese EPC contractor of wastewater treatment plants, and the company
has shown remarkable growth in a strategic market to LiqTech. This agreement with Denovo is a milestone for LiqTech in our efforts to penetrate the Chinese market for water treatment with our SiC membranes,” LiqTech CEO Lasse Andreassen stated in the press release.

Per the OEM agreement, Denovo will place progressive minimum order quantities for the years 2013-2016 in order to maintain the supply agreement.

For more information visit www.liqtech.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Immunomedics, Inc. (IMMU) Receives New Patent Notice for Antibodies Targeting CD19

Biopharmaceutical company Immunomedics, which is mainly focused on the development of monoclonal antibody-based products for treating cancer, autoimmune, and other serious diseases, announced today that it has received notice that its patent application for “Anti-CD19 antibodies” will issue as U.S. patent No. 8,337,840 on Dec. 25. The claims allowed under the patent will cover the use of specific humanized anti-CD19 monoclonal antibodies and their fragments for treating autoimmune diseases. The antibodies and fragments can be used alone, conjugated to at least one therapeutic agent, or combined with other humanized, chimeric, human, or murine monoclonal antibodies, like antibodies that are reactive with CD20, CD22, CD74, or HLA-DR.

Providing coverage until 2024, the patent also protects (19)-3s, which is a novel T-cell redirecting agent made as a DOCK-AND-LOCK (DNL) complex using Immunomedics’ patented platform technology. The DNL complex recognizes CD19 on B cells and binds to CD3 on T cells. At this year’s Annual Meeting of the American Society of Hematology, it was reported that (19)-3s was able to simultaneously bind to T cells and non-Hodgkin lymphoma cells – and induce T-cell-mediated killing of NHL cells at less than 1 picomolar (pM) concentrations in an ex vivo setting – with minimal activity at 10 pM.

This new patent offers protection for a new class of antibodies that complements Immunomedics’ current portfolio of humanized antibodies in its clinical pipeline.

Immunomedics has developed a number of advanced proprietary technologies, allowing the creation of humanized antibodies that can be either used alone in unlabeled “naked” form” or conjugated with radioactive isotopes, chemotherapeutics, cytokines, or toxins – creating highly targeted agents in each case. Using these technologies, Immunomedics has built a pipeline of therapeutic product candidates that utilize various different mechanisms of action. The company also has a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel DOCK-AND-LOCK (DNL) method in conjunction with Immunomedics for making fusion proteins and multifunctional antibodies, as well as a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pre-targeting methods. Immunomedics’ portfolio of intellectual property includes approximately 210 active patents in the United States and more than 400 foreign patents.

For more information, visit www.immunomedics.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Novatel Wireless, Inc. (NVTL) Reaches Three Million Unit Shipment Milestone of 4G LTE Devices and Receives Top Industry Awards for MiFi 2

Novatel Wireless, a prominent supplier of mobile broadband solutions, announced yesterday that since its first shipment in January 2011, Novatel has shipped over three million 4G LTE enabled mobile computing products. On top of reaching this impressive milestone, Novatel Wireless recently won two new LTE innovation awards and multiple Editors’ Choice accolades from tier-one publications for its new 4G LTE MiFi 2.

“We are pleased to celebrate our three millionth shipment of LTE enabled data-only mobile computing products and excited to be honored as the vendor providing continued innovation and the most advanced mobile broadband solutions in the market,” said Peter Leparulo, CEO of Novatel Wireless.

Novatel Wireless’ MiFi 4620L was recently named the winner in the Best LTE Device/Handset category of the 2012 Telecoms LTE North America Awards. The company’s innovative new product was also a CES Innovations Honoree in the Computer Accessories category of the Consumer Electronics Association (CEA)® 2013 Design and Engineering Award. AT&T recently released the MiFi 2 as the MiFi Liberate, and it has already been the recipient of an impressive number of industry awards and Editors’ Choice selections as the best performing and most advanced mobile hotspot on the market.

A recent review by GIZMODO, headlined “AT&T MiFi Liberate: The Best Mobile Hotspot I’ve Ever Used,” stated, “An AT&T LTE MiFi will change your life a little bit.” Highlighting the MiFi Liberate’s bright 2.8-inch color touch-screen display, it continued, “You normally use a computer to change a mobile hotspot’s settings. But this does it on the tiny screen, and it sets the Liberate apart from so much of the competition.” GIZMODO’s review added, “The best part [is] the battery life! This thing will go for days…”

A recent review in PC Magazine noted the advanced feature functionality, ease of use, and reliability of the MiFi Liberate. The review went on to say that the MiFi Liberate “gets you fast 4G LTE data speeds for more than 10 hours on a single charge, plus loads of additional features.” It continued, “The MiFi Liberate for AT&T takes mobile hotspots to the next level. It’s the best hotspot on AT&T, and our Editors’ Choice.”

“We believe our innovative approach, leading design and superior performance are vital factors when serving the mobile broadband market and we’re thrilled to see the acknowledgement and amazing feedback from editors and the industry,” Mr. Leparulo continued.

For further information, please visit www.nvtl.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Christopher S. Destro Joins Atossa Genetics, Inc. (ATOS) as VP – Sales and Marketing

Today, Atossa Genetics announced that Christopher S. Destro has joined the company as its new Vice President of Sales and Marketing. An industry veteran with over 16 years of successful sales and client management expertise, Mr. Destro will oversee product marketing, distribution, and sales. He will report to Dr. Steven C. Quay, MD, PhD, FCAP, Chairman, CEO and President.

“[Atossa] is very fortunate to have Christopher Destro join us as Vice President of Sales and Marketing at this pivotal time,” remarked Dr. Quay. “As we accelerate the national roll-out of our ForeCYTE and ArgusCYTE Breast Health Tests in early 2013, Chris’ extensive industry experience and in-depth market and technical expertise will be invaluable in helping us achieve our ambitious growth objectives.”

From 2007 to 2011, Mr. Destro held multiple prominent positions, including Vice President of Sales, North America, for three divisions of Magellan Biosciences where he managed sales of automated blood culture and automated susceptibility instrumentation for Trek Diagnostics, automated immunochemistry for Dynex, and a lead care platform for Point of Care testing. In July 2011, Thermo Fisher Scientific acquired Magellan, and Mr. Destro became a commercial leader of the Microbiology Division, working with national contracts, distribution channels, and direct sales in the clinical, pharmaceutical, and industrial markets. From 2000 to 2007, Mr. Destro served as Americas Sales Director for International Bioproducts, managing sales of core food pathogen diagnostic (ELISA) products while leading 17 distributors for the United States, Canada, Mexico and Latin America. Mr. Destro holds a Bachelor of Science degree in Microbiology from Ohio State University.

Mr. Destro said, “Atossa Genetics is an exciting and dynamic opportunity and I look forward to working with the team to commercialize the Company’s products and services for the benefit of millions of women. Atossa has already demonstrated the ability to make a difference in women’s lives. Over the past two decades, I have assembled and led teams that have achieved high growth in the diagnostic biotechnology solutions markets. I look forward to contributing to the next phase of Atossa’s growth as we expand the commercialization of our innovative products and services in the U.S.”

He continued, “One of the things that attracted me to Atossa is its novel and revolutionary approach to diagnosing, treating and preventing Breast Cancer. I believe this uniquely positions us to expand the commercialization of our potentially life-saving and market-changing solutions at a time when the need is greater than ever.”

On December 20, 2012, as incentive to join the company, Mr. Destro was awarded an option to purchase a total of 200,000 shares of Atossa’s common stock, par value $0.001 per share, outside the company’s 2010 Stock Option and Incentive Plan. The stock option has an exercise price equal to $4.11 per share, the fair market value on the grant date, and vests over a four-year period from his commencement of service.

For more information on Atossa Genetics, visit www.atossagenetics.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Synthesis Energy Systems, Inc. (SYMX) Engineer Study Will Devise Optimal Integration of Coal Gasification Technology

Synthesis Energy Systems, the coal and biomass conversion experts pioneering the forefront of a vast new territory opened up by the revolutionary U-GAS® gasification process developed via more than four decades of joint effort between DOE and the GTI (Gas Technology Institute), announced a key technology integration agreement today with an undisclosed, leading global tech provider. Due to extant confidentiality agreements surrounding this strategic move, the company is unable to disclose further details about said provider.

SYMX will be working to define a product that bridges the gap between the provider’s globally deployed process and the company’s own robust gasification technology, which has shown an exceptional capacity for handling a wide range of feedstocks. Backing the play by Synthesis Energy Systems will be top global logistics powerhouse, Fluor Corp. subsidiary, Fluor Enterprises, Inc., whose experience in providing construction, engineering, procurement, and maintenance to major companies across the globe will serve SYMX shareholders well. Fluor has played a key role in executing development on a majority of the gas-to-liquid facilities in operation today.

This remarkable announcement is a clear sign to the industry and could lead to a deployable JV architecture that would be a first industry-wide. A burgeoning new landscape thus opens before SYMX and management is moving rapidly to build up momentum for what is seen as a primary growth vector for the company’s gasification tech. The broad-spectrum input capability that the SYMX technology will bring to operations through such integration means that the provider will be able to utilize cheap, low-quality coal in an environmentally sound manner.

The company will spearhead an engineering study to define an optimized integration methodology for bridging the gap between both sophisticated technology end points (slated for about an eight-month window), and the results should indeed create a powerful new pipeline/workflow with huge, industry-shaking upside. The improved cost and efficiency targets this solution could hit are jaw dropping to say the least and this crucial study will be immediately followed up by the necessary plant integration estimates on how much it will cost to get a basic engineering package in and functional.

President and CEO of SYMX, Robert Rigdon, expressed the eagerness with which everyone at the company is greeting this huge opportunity to capture a “key component” of their overall vertical growth strategy, citing how remarkable the farm-out potential for this integration of complementary industrial technologies would be. The coalescence of in-house gasification expertise, a strong IP portfolio, and the company’s unique operational/maintenance experience will no doubt finely shape the final product of this study.

The study has all the potential to become a solid foundation for constructing a massive JV business for SYMX, a business which could completely transform the rapidly expanding space itself, as operators flock to a syngas coal hybridization solution. Rigdon pledged to redouble efforts at SYMX to harness the maximum potential of this opportunity for shareholders, and it is encouraging to see such a bold forward move in domestic coal utilization.

The effectiveness of U-GAS for gasifying abundant domestic coal reserves, especially when compared to competing technologies, is profound. Investors are encouraged to check out the technology and get a closer look at the potential business developing here for SYMX as a tech integrator/provider to operators struggling to keep up with an energy-hungry world.

For more information on Synthesis Energy Systems, visit www.SynthesisEnergy.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

ZBB Energy Corp. (ZBB) Announces Plans to Join the National Alliance for Advanced Technology Batteries (NAATBatt)

ZBB Energy, a leading developer of intelligent power and energy management technologies, announced that it will be joining the National Alliance for Advanced Technology Batteries (NAATBatt). The alliance will be holding an Annual Conference and Symposium on January 16-18, 2013, in Austin, Texas, where ZBB Energy will present “Ensuring Reliable Power in Unreliable Environments,” which highlights the enabling capabilities of ZBB’s comprehensive power control and energy storage technologies.

NAATBatt is a not-for-profit trade association of foreign and domestic corporations, associations, and research institutions focused on the manufacture of large format advanced batteries for use in transportation and large scale energy storage applications in the United States. Members range from advanced battery and electrode manufactures to material suppliers, vehicle makers, electric utilities, equipment vendors, service providers, universities, and national laboratories.

NAATBatt’s core missions are to grow the North American market for products incorporating advanced energy storage technology and to reduce the cost of those products to U.S. consumers. The core missions of NAATBatt are closely related. NAATBatt operates under the principal that the high cost of electrochemical energy storage, when compared to other technologies, serves as the primary barrier to widespread adoption of large format advanced battery technology. NAATBatt advocates for the adoption of public policies and the development of new technologies and industrial standards that will help reduce the cost to consumers of large format advanced batteries and the products that use them.

NAATBatt provides a platform for its members to work together across industry boundaries in order to address the challenges posed by the adoption of large scale electrochemical energy storage. NAATBatt programs aid in the advancement of energy storage technology and help promote best practices among industry members. NAATBatt helps make the advanced battery industry more efficient and successful by sharing networking opportunities and better information about the North American market for those companies that wish to serve it.

For more information on ZBB Energy, visit www.zbbenergy.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Consumers and Companies Ignore Fiscal Cliff

There are signs that the U.S. economy will get through the fiscal cliff just fine. Consumer spending rose in November by the most in three years and a gauge of planned spending by businesses also jumped higher according to government data.

The Commerce Department said today that inflation-adjusted consumer spending rose 0.6% in November. This was the strongest gain since August 2009. In addition, after-tax income climbed 0.8% inflation-adjusted.

In a separate Commerce Department report, a gauge of planned U.S. business spending rose much more than expected in November. Non-defense capital goods orders, excluding aircraft, jumped 2.7% in November. This was the second straight month of solid gains in this reading. The government reported that October’s reading was revised upward to 3.2% from the previously reported 2.9%. Overall durable goods orders rose by 0.7% in October.

Both readings have given an indication that, so far, few consumers or businesses are overly worried about Washington’s fiscal cliff. This is contrary to what many economists thought, that fears over what might happen would curtail spending.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

IGI Laboratories, Inc. (IG) Appoints Dr. Kenneth Miller as Senior Vice President – R&D

Yesterday, New Jersey-based generic topical pharmaceutical company IGI Laboratories announced that it has appointed Dr. Kenneth Miller as its Senior Vice President of R&D, effective December 17, 2012.

Jason Grenfell-Gardner, IGI’s President and CEO, remarked, “Dr. Miller’s appointment brings significant practical experience in generic topical pharmaceuticals and leadership that will allow us to accelerate the growth of our ANDA pipeline. This pipeline is the key to growing IGI’s generic business, and we’re excited to have Dr. Miller leading our R&D team.”

Dr. Miller has an extensive career with over 20 years of topical and transdermal experience in branded and generic pharmaceutical product development. Prior to IGI, he held various leadership positions at Mylan Technologies, eventually rising to Senior Director in 2008. As head of product development, Dr. Miller oversaw the development of topical and transdermal patches, including Mylan’s Fentanyl Transdermal System which received the DIANA Award for Best New Product Introduction in 2005.

In addition to his contributions to product development, Dr. Miller was responsible for technical evaluation of Mylan’s intellectual property, with four US Patents and six World Patents on product design and manufacture. Additional patents are currently pending.

Prior to Mylan, Ken held positions in both industry and academia serving on the faculties of UAMS (Pharmaceutics), Penn State (Chemical Engineering), and Utah (Dermatology). He has a BSChE degree from Carnegie Mellon University, an MSChE degree from West Virginia University, and a PhD from the University of Florida.

For more information, visit www.igilabs.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Unilife Corp. (UNIS) Announces the Commencement of Additional Unifill Stability Studies for Multiple Target Injectable Drugs

Unilife announced that an additional U.S.-based pharmaceutical company has begun stability and evaluation studies of the company’s Unifill syringe for use with multiple injectable drugs.

The target drugs – including pipeline drugs and commercially approved drugs that will benefit from lifecycle extension – are high-value therapeutics for chronic diseases requiring periodic injections. The new pharmaceutical customer is also reviewing additional Unilife devices for potential use with some of its other injectable drugs.

“The supply of Unifill syringes to this pharmaceutical customer for use with so many of their injectable drugs at one time is a major accomplishment,” said Alan Shortall, CEO of Unilife. “The customer cited the unique value proposition of the Unifill syringe, with its automatic, integrated and highly intuitive safety features, as a key factor in their selection process. This is not surprising, given how attractive and differentiated the Unifill syringe is compared to conventional prefilled syringe technologies.”

The commercial value of the solid relationship Unilife has established with this customer is anticipated to quickly grow beyond near-term device sales as the company formalizes a series of clinical development agreements and commercial supply contracts. Going forward, Unilife expects to generate accelerating, incremental revenues with this customer, with peak annual demand ranging between 25 million and 35 million units of Unifill every year for their initial target drug series.

The pharmaceutical customer is one of many such companies that have chosen Unlife’s devices to enable or enhance delivery and commercial success of their injectable therapies, and a substantial amount of business activity continues across Unilife’s commercial pipeline. In the past month, Unilife has met with senior executives from more than a dozen pharmaceutical companies as part of advanced, continuous discussions relating to every device platform across the company’s portfolio. Unilife looks forward to announcing the formalization of many of these commercial relationships in the near future.

The world’s first and only known prefilled syringe with automatic safety features fully integrated within the glass barrel, the Unifill ready-to-fill syringe is a primary drug container, safety device, and needle containment system all in one. Contrasted with ancillary safety products attached to prefilled syringes, Unifill has the capability to help streamline fill-fill systems and greatly reduce transport, packaging, and storage costs. Residing within the drug-fluid path are USP Class Six-compliant materials.

The Unifill syringe is designed to be safe, simple, and convenient for use by both healthcare workers and patients who self-administer prescription medication. An audible and tactile click signals both the injection of the full dose and the automatic activation of a needle retraction mechanism. Users can control the speed of needle retraction directly from the body into the barrel of the syringe, and the combination of the automatic, operator-controlled retraction features can help virtually eliminate the risk of infections from needlestick injuries, as the plunger is automatically locked after needle retraction to prevent reuse of the device and to encourage disposal.

The Unifill syringe is currently in production at Unilife’s York, Penn., facilities and is available for supply to interested pharmaceutical companies.

Unilife is a U.S.-based developer and commercial supplier of injectable drug delivery systems. The company’s broad portfolio of proprietary device technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, long-duration subcutaneous pump delivery systems, and targeted delivery systems. Each of these innovative and highly differentiated device platforms can be customized by Unilife to address specific customer, drug and patient requirements. Unilife’s global headquarters and state-of-the-art manufacturing facilities are located in York, Penn.

For more information, visit www.unilife.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Dendreon Corp. (DNDN) Completes Sale of New Jersey Immunotherapy Manufacturing Facility to Novartis Pharmaceuticals

Today, Dendreon announced it has sold its Morris Plains, N.J.-based immunotherapy manufacturing facility to Novartis Pharmaceuticals Corporation. The sale was a cash transaction totaling $43 million.

The agreement between the two companies represents a positive outcome for Dendreon and its shareholders, as well for the state of New Jersey. Dendreon continues making progress in improving its financial strength, and the transaction with Novartis aligns with that goal as the company works to build value for its shareholders. Approximately 100 of the existing employees at the Morris Plains facility will be able to retain their jobs and work for Novartis as that company builds out its immunotherapy operations and develops new treatments for patients.

The Morris Plains facility is a state-of-the-art building boasting 173,100 square feet and featuring pioneering capabilities for manufacturing PROVENGE (sipuleucel-T), which is the first autologous cellular immunotherapy to receive approval from the U.S. Food and Drug Administration to treat asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Dendreon announced earlier this year an intention to wind down PROVENGE manufacturing at the Morris Plains facility as part of a strategic restructuring plan to accelerate the company’s path to profitability and future growth.

Headquartered in Seattle, Wash., Dendreon is a biotechnology company focused on targeting cancer and transforming lives through discovering, developing, commercializing, and manufacturing novel therapeutics. Dendreon utilizes its antigen identification, engineering, and cell processing expertise to produce active cellular immunotherapy (ACI) product candidates that are designed to stimulate an immune response in various tumor types. PROVENGE (sipuleucel), the company’s first product, received FDA approval in April 2010. Dendreon is currently exploring the application of other ACI product candidates and small molecules to potentially treat various types of cancer.

For more information, visit www.dendreon.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Entropic Communications, Inc. (ENTR) Wins Prestigious 2012 Global Semiconductor Alliance Award

Entropic Communications, a world leader in semiconductor solutions, today announced that they were awarded the 2012 GSA Award in the “Most Respected Public Semiconductor Company Achieving $100 million to $250 million in Annual Sales” category by the Global Semiconductor Alliance (GSA).

The GSA’s mission is to accelerate growth and increase the return on investment of the global semiconductor industry by fostering collaboration, integration, and innovation among its industry. The GSA Awards are presented annually to outstanding semiconductor companies worldwide that have demonstrated excellence through their success, vision, and strategy. Award winners are selected by GSA members and are evaluated based on the products and future opportunities associated with a company’s silicon solutions and business model.

“We congratulate Entropic on receiving a prestigious 2012 GSA Award,” said Jodi Shelton, co-founder and president, GSA. “Entropic has undergone an impressive evolution over the past year, making two key acquisitions to further fuel Pay-TV operators’ shift from traditional broadcast to streaming, IP-based video delivery.”

Entropic is the only pure-play platform semiconductor company in connected home entertainment. The company offers a diverse portfolio of connectivity and set-top box (STB) system-on-a-chip (SoC) solutions that reliably and securely deliver and process multimedia digital content into and throughout the home.

“We are honored to be recognized by the GSA and our peers in the semiconductor community for our bold vision and successful execution in expanding our market opportunity in the competitive connected home entertainment market,” said Patrick Henry, president and CEO, Entropic. “With our expanded portfolio, we now offer best-in-class Connectivity and STB System-on-a-Chip solutions that seamlessly power and enable global Pay-TV operators to create more captivating whole-home entertainment experiences for their subscribers.”

In April 2012, Entropic completed its acquisition of Trident Microsystems’ STB SoC business which helped expand its presence in the connected home entertainment market by obtaining complementary assets, intellectual property (IP), patents, and core competencies. It also expanded the company’s international presence and diversified its revenue base. In July 2012, Entropic acquired specific direct broadcast satellite (DBS) IP and corresponding technologies from PLX Technology, Inc. This accelerated its DBS outdoor unit product roadmap.

The Global Semiconductor Alliance (GSA) addresses the challenges within the semiconductor supply chain including IP, EDA/design, wafer manufacturing, testing, and packaging to enable industry-wide solutions. The GSA identifies and articulates market opportunities, encourages and supports entrepreneurship, and provides members with comprehensive and unique market intelligence. Members include companies throughout the supply chain representing 30 countries across the globe. More information can be found at www.gsaglobal.org.

Entropic Communications is a leading global provider of silicon and software solutions that enable connected home entertainment. Entropic transforms how traditional HDTV broadcast and streaming video content is available, ensuring seamless, reliable, and securely delivered, processed, and distributed content into and throughout the home. Entropic’s next-generation home connectivity and set-top box system-on-a-chip (SoC) solutions enable Pay-TV service providers to offer consumers a more captivating whole-home entertainment experience by delivering new, high-performing ways to connect, engage, and enjoy multimedia content. For more information, visit www.entropic.com.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Excitement at VistaGen Therapeutics (VSTA) Continues to Build

A lot of great things have been happening with VistaGen Therapeutics recently. VistaGen is a California-based biotechnology company actively applying its proprietary human pluripotent stem cell technology to launch a new era of drug rescue, predictive heart and liver toxicology, and drug metabolism screening.

VistaGen’s unique stem cell technology-based Human Clinical Trials in a Test Tube™ platform currently involves controlled differentiation (development) of pluripotent stem cells into mature, functional human heart and liver cells that can then be used to predict early in development whether a drug candidate has potential toxicity problems. Determination of potential heart and liver toxicity early on in the development process, far earlier than standard tests, means that drug candidates have a chance of being modified for a successful outcome long before resources are expended on costly and time-consuming animal and human clinical studies. Many otherwise promising drug candidates have been shelved due to heart or liver toxicity issues that surfaced well into the development process and even after FDA approval, representing major losses for drug companies.

By generating new chemical variants of small molecule drug candidates that have shown promise, but are currently on hold due to heart or liver toxicity issues, VistaGen can effectively rescue substantial prior investment by others in discovery and development of the once-promising drugs, building an exclusive and valuable portfolio of proprietary rejuvenated drug candidates. VistaGen plans to have economic participation rights to all of the drug rescue variants it develops, benefitting its bottom line as well as its shareholders. The tremendous promise of this approach has prompted the company’s CEO, Shawn Singh, to purchase 100,000 additional common stock shares of the company, bringing his total holdings to 252,174 shares.

Other recent developments include the company’s formalized membership in the Toronto-based Centre for Commercialization of Regenerative Medicine’s (CCRM) Industry Consortium. VistaGen aims to expand the commercial applications of their Human Clinical Trials in a Test Tube™ platform by building multi-party collaborations with CCRM and members of its Industry Consortium around drug rescue and regenerative medicine opportunities, including pilot nonclinical programs involving blood, heart, liver, and potentially pancreatic beta islet cells. Speaking of these opportunities, Shawn Singh emphasized that such collaborations have the potential to “transform medicine and accelerate significant advances in human health and wellness that stem cell technologies and regenerative medicine promise.”

In addition, the company had earlier announced the completion of a $3.25 million financing commitment from its largest institutional investor, Platinum Long Term Growth VII, LLC.

For additional information on VistaGen’s stem cell technology and current initiatives, visit www.VistaGen.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Orexigen Therapeutics, Inc. (OREX) Completes Light Study Patient Screening, Presents New Obesity Therapeutics Market Research

Obesity-focused biopharmaceutical company Orexigen Therapeutics has provided a clinical trial update of the Light Study and results of recent market research at its Analyst Day meeting in New York City, which took place Dec. 18.

The company has reported that the screening of new patients has been completed for the Light Study, which is a cardiovascular outcomes trial evaluating Contrave (Naltrexone SR/Bupropion SR). Within the next few weeks, around 9,000 patients will be randomized in the study. An interim analysis will occur after approximately 87 major adverse cardiovascular events (MACE) are accrued in the Light Study. While it is still too early to predict the rate of MACE, Orexigen anticipates resubmitting the Contrave New Drug Application and conducting the interim analysis in 2013, with potential approval as early as the fourth quarter of 2013, if the annual rate is close to the targeted 1.5 percent.

“With great performance from our clinical sites and with the help of our partners, including Blue Chip Marketing Worldwide, the Orexigen team deployed several innovative strategies and tactics to enroll the Light Study in just six-and-a-half months,” said Michael Narachi, CEO of Orexigen. “We now look forward to 2013, when we anticipate being able to provide interim data from the Light Study to the FDA and CHMP for review and potential approval in the U.S. and Europe.”

Orexigen also discussed recent physician and patient market research, which was conducted to determine potential growth of the obesity therapeutics market and preference shares between Contrave and two recently approved obesity therapeutics. Conducted with 1,000 physicians, the quantitative market research suggests that the market for obesity therapeutics could grow threefold to fourfold – from a 2012 base of around 7.8 million prescriptions – within five years. The physician research additionally indicates that, if approved, Contrave would be favorably perceived among the new product entrants. This was particularly true among certain important patient profiles, including some or all of the following characteristics: female, a body mass index between 30 and 40, and diabetes.

An additional market research study conducted by the company surveyed more than 5,000 patients in order to assess interest levels between Contrave and those same two recently approved obesity therapeutics. This study’s results suggest attractive patient interest levels for Contrave – particularly across specific important segments of the obese and overweight patient population, which supports the physician research findings.

“Our extensive market research demonstrates the potential for the obesity therapeutics market to grow three-to-fourfold in the next few years, as multiple new drugs with different mechanisms of action become available, giving prescribers and patients new tools to fight obesity,” said Mark Booth, chief commercial officer of Orexigen. “We were also pleased with how Contrave performed in this research across the most important patient demographic segments.”

A webcast of the presentations made at Analyst Day can be accessed live on the “Investor Relations” section of the Orexigen Web site, www.orexigen.com, and will be archived for 14 days following the event.

Orexigen Therapeutics is a biopharmaceutical company focused on the treatment of obesity. The company’s lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The company’s other product candidate, Empatic, has completed Phase II clinical trials.

For more information, visit www.orexigen.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

UniTek Global Services, Inc. (UNTK) Introduces New Brand, Pinnacle Wireless

UniTek Global Services, a prominent supplier of permanently outsourced infrastructure services in the telecommunications, broadband cable, wireless, two-way radio, transportation, public safety, and satellite industries, today introduced Pinnacle Wireless, a new brand identity for its recently integrated carrier and specialty wireless business unit, which has been merged into a single, customer-facing organization. Moving forward, UniTek intends to direct its focus towards large, long-term strategic network development projects to best serve its customers’ and overall industry needs.

“The name, Pinnacle Wireless, exemplifies what we aspire to be – the top solutions provider in the wireless industry,” said Michael Hayford, President of Pinnacle Wireless. “The newly launched Pinnacle Wireless brand represents the strength of our unified organization. We have a nationwide infrastructure, strong engineering and system integration offerings, and extensive project management capabilities across a variety of wireless applications. We expect this expertise in the wireless industry and our proven ability to execute will position us for greater success in the rapidly expanding marketplace.”

The company showcases continual expansion in the wireless market with recent contract awards of approximately $15 million, representing incremental backlog since September 29, 2012. Pinnacle Wireless has bolstered its involvement in the World Trade Center redevelopment and was awarded an additional $7.5 million of work in 2012. Additionally, Pinnacle Wireless has won several new contracts to develop integrated wireless networks regionally for public safety, mass transit, and various commercial applications. The most recent contract awards will deliver wireless services for the New York City Transit, the Fire Department of New York, and the New York Police.

The new Pinnacle Wireless will unite UniTek’s powerful national presence and shared services platform with its own innovative range of technology solutions, including the capability of delivering “end-to-end” wireless solutions and services for an expansive customer base. The company plans on building upon its sterling reputation and success in the Northeast to grow its complete wireless lifecycle management and deployment expertise nationwide. UniTek aims to strengthen existing customer relationships and develop operations in major markets where the company already has an established presence in satellite and cable fulfillment operations. Coupled with this established presence, is a workforce of over 5,000 talented employees. Pinnacle Wireless expects to apply its scalability in the creation of new service offerings to address the needs of national business initiatives supported by leading manufacturers and Tier 1 Systems Integrators.

“We believe we can leverage the strength of the Pinnacle brand and its decade-long position as a leading developer of large-scale specialty networks in the public sector and enterprise markets in the Northeast. We offer our customers a robust suite of services in the engineering, installation and management of industry-leading solutions, which we expect to help drive our geographic expansion,” added Stan Jones, Senior Vice President of Sales and Marketing. “We are committed to our goals of growing the Pinnacle Wireless brand, expanding our wireless customer base and increasing our market share.”

UniTek is in the process of re-branding its vehicles, website, and marketing materials. The company expects this transition to be seamless for existing Pinnacle Wireless customers, vendors, and employees.

For further information, please visit www.unitekgs.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

GigaMedia Ltd. (GIGM) Demonstrates New Cloud Platform GigaCloud, Addresses Underserved Market Needs

GigaMedia, a diversified provider of online games and cloud computing services, yesterday previewed its new, self-developed GigaCloud platform at an event in Taipei. The company also demonstrated a host of new products at the event, which was attended by the media, industry professionals, and potential partners.

GigaCloud is an integrated platform of cloud-based tools and services for SMEs. The platform provides a simple and efficient way for SMEs to outsource their critical IT needs and upgrade their business with technology that provides such things as cost savings, productivity improvements, and flexibility.

Collin Hwang, GigaMedia Chief Executive Officer, said, “We are delighted to unveil our cloud offerings and begin educating the market on the benefits our services will provide. Many SMEs rely on legacy IT and communications systems and have no in-house IT support; they need flexible, mobile and affordable technology solutions that leverage the Web to improve their business, which is driving a global migration to new cloud solutions.”

“Our bundled solutions will allow SMEs to get their businesses online and collaborating faster, delivering significant productivity gains and dramatically lowering telecommunications costs,” continued CEO Collin Hwang.

Traditional communication systems can be extremely expensive, costing thousands of dollars to establish with varying monthly maintenance fees. By eliminating the need for complex hardware, length installation, and technical support, GigaCloud provides SMEs with the power of flexibility of advanced communication systems that are simple, affordable, and accessible both in the office as well as remotely.

GigaCloud will initially include the following bundle of services:

• Cloud-based PBX services that greatly lower telecom costs and increase quality and flexibility, including unlimited local and reduced rate domestic and international long distance service;
• Cloud storage for file and data editing and sharing anywhere, anytime;
• Cloud faxing with Web-based transmission and storage making faxing simple and mobile;
• Video surveillance, including a Web cam that will allow for off-site monitoring; and
• Cloud leasing, including leasing of cloud services and related hardware that will provide SMEs an affordable way to grow.

Currently, cloud services for SMEs in Taiwan and mainland China is a largely untapped opportunity and lags the US in adoption. With over one million SMEs in Taiwan, forecasts show that SMEs will drive strong growth of cloud services regionally.

To aid with market penetration, GigaMedia has formed a strategic partnership with Taiwan-based Chailease Holding Co. Ltd for product launch to capitalize on the firm’s large SME customer base. With approximately 42 percent market share, Chailease is Taiwan’s number one leasing company. Chailese serves approximately 15,000 SMEs in Greater China and offers a wide array of products, including financial services, leasing, and installment sales.

GigaMedia has already addressed plans to expand the scope and reach of its services going forward via the use of additional strategic channel and technology partnerships.

Launch of GigaCloud is slated for March 2013.

For more information on GigaMedia, visit www.gigamedia.com.tw

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

ModusLink Global Solutions, Inc. (MLNK) Becomes Full Member of Electronic Industry Citizenship Coalition

ModusLink Global Solutions is a company that executes comprehensive supply chain and logistics services that improves clients’ revenue, cost, sustainability, and customer experience objectives. The company is a trusted provider to the world’s leading companies in consumer electronics, communications, computing, software, medical devices, retail, and luxury goods.

The company announced today that it has become a full member of the Electronic Industry Citizenship Coalition (EICC) after two years as an applicant member. The EICC brings together a wide range of companies, including the leading brands, in the electronics industry to address issues of social, ethical, and environmental concern in the supply chain.

EICC members adopt a code of conduct and an auditing process that is designed to ensure each company operates in compliance with strict guidelines for labor and human rights, worker safety, and health, safeguarding the environment and doing business with a high degree of integrity. Members are also required to have their suppliers implement the code of conduct.

ModusLink feels that social and environmental responsibility has become a baseline requirement of doing business in the supply chain and logistics space. It offers many supply chain and logistics services designed specifically to improve its customers’ sustainability efforts. To see what services are offered by ModusLink, please visit www.moduslink.com.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

GreenHunter Energy, Inc. (GRH) Expands Appalachia Transport Fleet Capacity Ahead of Disposal Upgrades, Adds HAZMAT Certification

GreenHunter Energy today updated markets on the status of their wholly owned GreenHunter Water, LLC subsidiary, reporting that the company has put in orders to expand the size of its trucking fleet serving the unconventional shale operators in the Appalachians (Marcellus and Utica plays in Ohio, Pennsylvania, and West Virginia).

President and COO of GRH, Jonathan Hoopes, commented on the addition of the six new Peterbilt 388 Bobtails (three with 100 bbl vacuum tanks and three with identical tanks certified for HAZMAT), noting that the company is running at full capacity in the region and could really use the new operational muscle. The expansion of the Appalachia truck fleet from a mere five at the outset of 2012, to now 31 transport trucks, is a clear indication of the direction GRH is headed and as more and more regional operators come to know/rely on the exemplary services the company can provide, the fleet will likely expand further.

When you throw in the new GRH disposal facilities slated to come on-line relatively soon, you can see that the company is prepping for increased business volume, balancing out the trucking capacity and disposal capacity ahead of growth perfectly. Today’s announcement is also something of a milestone for regional operations as the company has hitherto lacked certified equipment for handling liquids mixed with hydrocarbons, something which is generally no problem since the vast majority of such hydrocarbon-laced water is usually gravity separated on-site anyways. However, there are some pads in this difficult terrain that don’t have the equipment for this kind of on-site separation and thus GRH can now capture even more market space through the fleet expansion, offering a potentially clutch service to this growing customer-base.

This move basically puts GRH in the oil transport business while riveting on some much-needed capacity in the thriving, hydrocarbon-rich Appalachia region. This region has a solid future for such production, so it makes good sense for the company to be growing their overall infrastructural footprint at this phase. A winning combination of absolutely vital water transport and disposal well services has quickly built up a warm brand identity for the company among sector operators doing difficult work in this difficult region.

In the Appalachians the work is dirty, difficult, and brutal. Companies like GRH, who put the operator’s needs first and have capacity on-site, on time, and ready to go when it’s needed can make a killing here. GreenHunter really has put together an attractive portfolio of Total Water Management Solutions™ for these guys, with several key innovations developed from an operator-centric point of view, like the flexible Frac-Cycle™ system that allows flowback and produced water to be recycled into clean brine or fresh water, their bleeding-edge well head management and compliance solution RAMCAT™ (Remote Access Management Compliance Asset Tracking), or the company’s latest edition, a completely customizable, 10k plus bbl temporary water storage tank system (complete with robust interlocking steel panels for safe/rapid deployment), the MAG Tank™.

As part of the purchase, GRH has bolstered an existing commercial loan facility with a local bank in the heart of the Appalachians, bumping the window up to $3.3M. GreenHunter expects to take delivery of the new hardware early in 2013 (late January) and will be offering this new capacity to hungry hydrocarbon developers in the region as soon as late Q1.

For more information on GreenHunter Energy, visit www.GreenHunterEnergy.com

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

General Moly, Inc. (GMO) Ready to Break Ground on Construction at Mt. Hope Project in Nevada as Reclamation Bonding Clears BLM

General Moly, the Colorado-based mineral developer focused on pure-play molybdenum projects with two primary sites in Nevada, the Mt. Hope (80% owned) and Liberty (100%) projects, reported today via the company’s Mt. Hope subsidiary, Eureka Moly, LLC,
that the BLM has accepted reclamation bonding for the Mt. Hope project and cleared the company to proceed with breaking surface at the site.

The reclamation permit, based on a site specific application that validated the company’s proposed methodology for taking the site through reclamation and into productive post-mining land use, issued by Nevada’s Division of Environmental Protection (Nov 19), also cleared the $73M cost estimate and laid down the financial guarantee structure around this estimate necessary to proceed. Having organized a surety underwriters group through Marsh USA Inc., thus satisfying the financial guarantees required by BLM stipulations in the Record of Decision, GMO is ready to begin construction of facilities on the moly-rich Mt. Hope property, considered to be one of the largest, highest grade moly deposits on earth.

With funding for the surety program coming in well in-line with August 2012 capital estimates for the job at around $17.2M, the initial cash outlay of $5.6M made, and JV partner POS-Minerals Corp. at the ready to also fund the construction phase remainder, GMO will be looking to start early well field development very soon. Heavier facility construction can begin in the spring and until then the company will be mostly doing site prep alongside the light construction, “clearing and grubbing,” as COO of GMO, Bob Pennington put it.

With estimated reserves as some 572M tons grading 0.085% moly on a mine life of over 58 years (Exxon, 1988), Mt. Hope is an exceptional domestic source for this crucial substance that is needed widely as an alloy for making high-strength steel, as well as being used in the petroleum industry for cracking sulfur out of fuel (and many, many more uses).

That $17.2M figure covers approximately three years and should take the company well into development at Mt. Hope, giving GMO a strong second pillar to go along with their Liberty project in the Tonopah area (29M tons of ore produced between 1981-1991 grading 0.11%). Molybdenum is one of the inescapably vital fundamental resource commodities for the global economy moving forward and this is a superb opportunity for investors to get in at the ground floor with a domestic company that is bucking to become one of the world’s top names in moly production.

For more information on General Moly, visit www.GeneralMoly.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Metabolix, Inc. (MBLX) Polymeric Modifier for PVC Now Available for Shipping

Metabolix is an innovation-driven bioscience company delivering sustainable solutions to the plastics, chemicals, and energy industries. The company is developing and commercializing a family of high-performance biopolymers targeted to the markets for film and bag applications, performance additives, and functional biodegradation.

The company today announced that 16001, a bio-based polymeric modifier for PVC (polyvinyl chloride) formulations based on Metabolix PHA resin, is now available for shipment to customers. Metabolix designed 16001 as a performance additive to improve the mechanical and environmental performance characteristics of PVC.

Metabolix’s researchers have developed a series of PHA-based polymeric modifiers that showed significant improvements in the modification and processing of PVC. Its modifier significantly improves impact resistance and toughness in rigid and flexible PVC applications without compromising PVC transparency or UV stability. The PVC market is a rather large one, with an estimated market demand of 35 million metric tons per year.

The company is developing an entire series of second generating products in the modifier space that the company plans to launch in 2013. For additional information about Metabolix and its entire product line, please visit www.metabolix.com.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Excellagen Plays Leading Role for Cardium Therapeutics, Inc. (CXM)

A major part Cardium’s product candidate portfolio, and the company’s overall strategy, is Excellagen, an acellular biological modulator for advanced wound care management. Cardium’s strategic goal is to develop a portfolio of medical product candidates at various stages of development and to commercialize these products in a timely and effective manner. Excellagen is well down that path, being FDA-cleared, and the company is already seeking commercialization partners for its marketing and sales.

Excellagen is a pharmaceutically formulated bovine collagen gel used to facilitate the healing of many types of wounds. During manufacture, the collagen is purified using a specialized process that removes impurities (including endotoxins), denatured molecules, and collagen fragments. Excellagen promotes chemotaxis, cellular adhesion, migration, and proliferation to stimulate granulation tissue formation. Applied immediately following debridement and in the presence of blood, Excellagen is designed to activate human platelets, triggering the release of platelet-derived growth factor. The flowable, ready-to-use formulation is ideal for use in wounds of varying shapes and surface contours, as well as tunneled/undermined wounds where sheet-based products are not adequate.

Key benefits of Excellagen:

• It comes in the form of ready-to-use, pre-filled sterile syringes, minimizing preparation time
• It is simple and easy, a major preference of physicians, involving no thawing or mixing
• It is flowable, with no sutures or staples required
• It is a viscosity-optimized gel that is dripless, providing complete wound coverage
• Only a thin layer is required
• Treatment is needed at only one or two week intervals

Excellagen is already FDA-cleared for the treatment of neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds. It is intended for professional use following standard debridement procedures (the removal of dead tissue and foreign mater) in the presence of blood cells and platelets, which are involved with the release of growth factors.

Case studies have shown a rapid onset of the growth of important granulation tissue in a wide array of wounds treated with Excellagen.

For additional information, visit www.CardiumTHX.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

Sutor Technology Group Ltd. (SUTR) Sees Changes to its Management Team

Yesterday, leading China-based steel products manufacturer, Sutor Technology Group, announced that it has appointed Naijiang (Eric) Zhou as its Chief Financial Officer, effective December 14, 2012. This position follows his current role at Sutor as the Vice President of Finance, which he has held for the last three years.

Prior to Sutor, Mr. Zhou worked in various capacities for Rich Fields Investment, Roth Capital Partners, American Electric Power, The Wing Group, and U.S. Global Investors, including executive vice president, chief financial officer, research analyst, financial analyst, and principal financial planner. He has over 15 years of professional experience in the private equity, mutual fund investment, equity research, and Fortune 500 corporate financial planning industries.

Mr. Zhou holds a Ph.D. in energy and mineral resources and an MBA in finance degree from the University of Texas at Austin and a B.Sc. in Petroleum Engineering from China Petroleum University. He also holds the Chartered Financial Analyst (CFA) designation.

In other company news, Yongfei Jiang resigned as Sutor’s Chief Financial Officer, Treasurer, and Secretary, effective December 14, 2012. Mr. Jiang will continue to work for the company and will be responsible for planning and supervising its corporate development and strategies. His resignation is not the result of any disagreement with the company on any matter relating to its operations, policies, or practices.

On the same date, Mr. Zhuo (Jason) Wang, currently the Director of Investor Relations, was appointed as Treasurer and Secretary of Sutor Technology Group, effective December 14, 2012.

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html

TeleCommunication Systems, Inc. (TSYS) Launches Next-Gen 911 System

TeleCommunication Systems recently announced its new suite of Next Generation 911 (NG 911) systems. This comes after the acquisition of microDATA in July of 2012. The new NG 911 system is fully NENA i3 compliant and provides services to wireline local exchange carriers, VoIP service providers, competitive local exchange carriers, and wireless operators. It combines TCS’ carrier-grade Emergency Services IP Network (ESINet) and national text gateway with microDATA’s ESINet and CPE solution.

Based in Annapolis, MD, TeleCommunication Systems is focused on the development of mobile communication technology, with components in E9-1-1, text messaging, commercial location, and deployable wireless communications. The company is also involved in cloud computing, wireless applications for navigation, search, asset tracking, social applications, and telematics. The company has clients in government agencies utilizing TeleCommunication cyber security expertise, professional services, and highly secure deployable satellite solutions for mission-critical communications.

TeleCommunication claims that several technologies are evolving to bring their NG 911 systems to life: legacy circuit-switched infrastructure is being upgraded to all-IP-based systems, and SMS services are being accepted. This will allow wireless operators to utilize TeleCommunication’s cloud-based services, as well as allow the public the ability to quickly send information such as addresses, photos, and videos to emergency responders.

Ron Westfall, research director, Service Provider Infrastructure, Current Analysis, said, “NG 9-1-1 is the future of emergency communications and response. This pivotal transition will provide the public with options to contact emergency services through the communication pathway that best suits their needs. TCS commands the experience and market position to drive the transition for wireless carriers and PSAPs across the United States.”

Chris Nabinger, senior vice president and general manager, Safety & Security Group, TCS, said, “Over the past decade, the ways in which people communicate have radically changed; therefore, the method in which the public contacts 9-1-1 dispatchers must keep pace. NG 9-1-1 not only addresses the public safety needs of tomorrow, but it also solves many of the challenges we face today. Our 2012 acquisition of microDATA, combined with our expertise in delivering wireless E9-1-1, optimally positions TCS to deliver this comprehensive suite of NG 9-1-1 solutions to enable fast and detailed emergency communications while increasing interoperability between PSAPs.”

For more information, visit www.telecomsys.com

About MissionIR 

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

Sign up for “The Mission Report” at www.MissionIR.com

Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html